Ribosomal protein L26 pseudogene 36 (RPL26P36)

RPL26P36 is a pseudogene generated by duplication or retrotransposition of the functional RPL26 gene (ribosomal protein L26). Unlike the protein-coding parent gene, it does not produce a functional protein and has no known demonstrated biological activity. The human genome contains thousands of ribosomal protein pseudogenes such as RPL26P36[3][4]. These are typically nonfunctional "genomic fossils"; some can occasionally be transcribed, but almost never encode active proteins or participate in cellular processes[3]. RPL26P36 is not a recognized therapeutic target (not a receptor, enzyme, transporter, transcription factor, or any drug-accessible entity)[3][4][6]. It is not typically involved in disease, nor does it serve as a biomarker or interact with drugs. Some ribosomal protein pseudogenes have limited relevance in genomic studies or evolutionary analyses but lack direct medical or therapeutic impact[3][4][6]. The functional parent gene, RPL26 ("Ribosomal protein L26"), encodes a structural protein of the large 60S ribosomal subunit and plays a role in protein synthesis and regulation of mRNA translation, including the modulation of p53 translation[1][4][5][6]. The pseudogene RPL26P36 is not referenced in disease associations, therapeutic strategies, or pharmacological databases; structured information is unavailable beyond its existence as a pseudogene[3][6]. The large number of ribosomal protein pseudogenes is a hallmark of genomic complexity but poses challenges for genetic annotation due to lack of functional relevance[3][4][6]. In summary: RPL26P36 (Ribosomal protein L26 pseudogene 36) is a non-coding pseudogene associated with the functional RPL26 ribosomal protein gene. It is not a therapeutic target, has no documented biological or clinical role, and is considered incorrect for queries related to drug targets, biomarker identification, or disease mechanisms[3][4][6].

Other names

RPL26P36RPL26_16_1792